Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 12/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167811 | 0.83 | KMT2A (0.55) | KMT2AMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL6168320 | 0.81 | TGFBR1 (0.44) | MAPTALDH1A1 | |
| SCHEMBL6757634 | 0.81 | TGFBR1 (0.67) | KMT2AMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL6621746 | 0.81 | POLB (0.52) | KMT2AMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL6169245 | 0.80 | PDE3B (0.46) | — | |
| SCHEMBL6168835 | 0.79 | MAPT (0.53) | KMT2AMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL6169255 | 0.78 | HTT (0.48) | — | |
| SCHEMBL411631 | 0.78 | TGFBR1 (0.46) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6170719 | 0.76 | HTT (0.58) | — | |
| SCHEMBL6175922 | 0.76 | TGFBR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | GELLIBERT FRANCOISE J (FR) | 2005-07-28 | — | — | US | claimed |
| EP-1506191-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-16 | — | — | EP | claimed |
| WO-2003097639-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | GELLIBERT FRANCOISE J (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1506191-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097639-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | ACVR1, TGFBR1, SMAD3 | KMT2A 3214/4885MAPT 1751/4885KDM4E 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.